chrisvoncsefalvay/vaers-outcomes huggingface dataset:
10 days after the booster shot I started to get hives on the back of my neck, they moved around my body for the next 6 days and I would also get red patches where ever the skin was rubbed from clothing. I started to take 20 MG of Pepcid AC and 10 MG of Zyrtec twice a day which has helped with the outbreaks of hives. I still get hives near my eyebrows, ankles, wrists, etc. but they are not itchy and still get red patches on areas of friction and on face after showering. I have a prescription for Prednisone, but have not started it. This is 100% a reaction to the booster shot. It is more common than spoken about and there are plenty of anecdotal stories to back this up. I rarely get sick, maybe a cold once every three years, I work out 4-5 times per week, do not drink or smoke, and eat well. I have no known allergies and have never had hives before in my life.
Immediately after vaccine delivered, the deltoid became red, mottled and slightly warm. It was not painful, not swollen. 25 mg of BENADRYL was given PO and reaction resolved within 15 minutes.
This study case was received from the investigator on 09 August 2012. A male subject (date of birth not reported) with no reported past medical history was found to have on 01 August 2012 an elevated Troponin level of 1.11 ng/ml 14 days after the subject had received on 18 July 2012 the following vaccines: ACAM2000 (lot number, route and site of administration not reported) and an injection of TYPHOID VACCINE (lot number, route and site of administration not reported). On 30 July 2012, the subject's smallpox injection site was reported to look "fine". The subject reports no chest pain, no cardiac adverse events (AE's), no AE's, no new concomitant medications (con-meds) and no HURT was marked on Wong Baker scale. Laboratory tests (Labs) were drawn and a "rapid test" was negative. On 01 August 2012, the subject was notified of elevated Troponin level and was scheduled to be reevaluated the next day. On 02 August 2012, the subject returned for evaluation of elevated Troponin at 1.11 ng/ml. The subject reported no chest pain or any other cardiac AE's. The subject's Troponin level was 1.02 ng/ml and EKG was normal. The subject was referred to his primary care provider immediately and health services. According to the investigator, the subject had asymptomatic Troponin elevation, trending down with a normal EKG. "No treatment or further workup necessary at this time". No further information was available at the time of the report. The subject's outcome was residual effects still present (not recovered). This represents a case of potential myopericarditis per the Investigator and has subsequently been referred to the Adjudication Committee for assessment. Documents held by sender: none.
Knots at injection sight that were hard and lasted over two weeks time.  Profuse vomiting on third day out from vaccination date. Intense screaming spells that take place at random and last any where from five mintes to one hour and fifteen minutes.
Started feeling light headed 15 to 20 minutes after getting the vaccine.Had tachycardia for 2 to 3 minutes.Lightheadedness lasted about 10 minutes.Next morning woke up with true vertigo .Lasted few minutes.That night mild vertigo returned, mostly positional.Ever since mild light headedness.Have to sleep in a recliner.Vomited once, but continue  to have mild nausea.
Information has been received from a physician concerning a 53 year old female patient with a history of bone marrow transplant who on 24-MAR-2010 was vaccinated with a dose of PNEUMOVAX 23 instead of PREVNAR. It was recommended by the patient's oncologist that the patient received "PNEUMOVAX 7". It was believed the oncologist meant PREVNAR. The patient had not experienced any known symptoms. It was unknown if patient sought medical attention. Additional information has been requested.
Case number PHEH2014US018443 is an initial spontaneous report received from a nurse on 11 Sep 2014 with a follow up information received from the nurse on 10 Dec 2014. This case refers to a 16 year old female patient. Her current conditions included vitamin deficiency, anemia and contraception. Her concomitant medications were vitamin D3 at a dose of 200 IU via oral route daily for vitamin deficiency, ferrous sulphate 325 mg via oral route daily for anemia and DEPO PROVERA 150 mg intramuscularly every three months for contraception. Her vaccinations were updated and vaccination history included a dose of MENVEO (batch number: not reported) which was well tolerated. She was vaccinated with a booster dose of MENVEO (batch number: X12097/A12097) at a dose of 0.5 ml intramuscularly on 11 Sep 2014 at 9:55 am, which was reconstituted with an expired lyophilized vial. No adverse event was reported following this administration error. Follow up information received from the nurse on 10 Dec 2014: Patient demographics (height and weight), vaccination history, current conditions and concomitant medications updated.
The patient stated that a few days after she received the immunization her arm became very swollen and was treated for cellulitis.
BLOOD CLOT IN LEFT CALF; This spontaneous report received from a patient via a company representative through social media concerned a male of unspecified age and ethnicity. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown and expiry: Unknown) dose, start therapy date were not reported, 1 total, administered for prophylactic vaccination. No concomitant medications were reported.  On an unspecified date, the subject experienced blood clot in left calf. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of blood clot in left calf was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0;0210517568-covid-19 vaccine ad26.cov2.-Blood clot in left calf. This event is considered unassessable. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event.
Nausea and vomiting within 5 minutes of the injection that progress to dizziness, diaphoresis,  and pallor.
This case was reported by a nurse and described the occurrence of arm pain in a 41 yr old female pt who received hep B vaccine recombinant (Engerix B) injection for prophylaxis. On 18Dec03 the pt received the second dose of Engerix B (lot ENG5465A6, 04Dec04) and at an unspecified time the same day experienced arm pain. The immunization series with Engerix B was discontinued. As of 27Jan04, the event was unresolved. The nurse considered the event to be related to vaccination with Engerix B.
On 3/23, I started feeling odd. My apple watch alerted me that my heart rate had dropped under 40 BPM for 10 minutes. I then made an appointment with my PCP for the following day. They did a EKG and I was diagnosed with Mobitz type 2, but he referred me to a Cardiologist. Cardiologist Dr had me do a stress test and wear a holter monitor for 2 weeks, that confirmed my original diagnosis of Mobitz type 2 block, which ended in me having to get a pacemaker on 6/14.
Awful achiness, toes, fingers everything hurts .  Swollen knot or lymph node under my right arm., tired, ans woke up with cold sores in my mouth
pt recvd vax; 20 days after vax, pt devel a delayed hypersensitvity rxn, including urticaria;
felt dizzy; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: DIZZINESS (non-serious), outcome "unknown", described as "felt dizzy". Additional information: The following day after getting the vaccine, he took multivitamins and felt dizzy. He also wanted to confirm how long he needed to wait before he could drink alcohol after the vaccine.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
1st dose on DEC-2021, 2nd on 16-SEP-2022; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 59-year-old female patient who received Herpes zoster (Shingrix) (batch number Y7D4B, expiry date 31st August 2023) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in December 2021).   On 16th September 2022, the patient received the 2nd dose of Shingrix. On 16th September 2022, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK receipt date: 21-Dec-2022 Reporter's comment: Information for adverse event was collected. The vaccine administration facility was the same as primary reporter. The call was escalated to second line. The reporter consented to follow-up. Additional supportive information: The patient received 2nd dose of Shingrix later than the recommended interval, which led to lengthening of vaccine schedule.
Presented to ED w/ generalized weakness, diarrhea, and overall sense of not feeling well; patient was noted to be positive for COVID-19; tx with abx, remdesivir, O2.
Left arm pain, left upper back pain, lower back pain, and buttock pain all subsided after 4 days except the buttock pain and is still lingering
TEETH STARTED CRACKING WHERE HAD FILLINGS AFTER THE SHOT IN 2 WEEKS; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient experienced teeth started cracking where had fillings after the shot in 2 weeks. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of teeth started cracking where had fillings after the shot in 2 weeks was not reported. This report was non-serious.
This spontaneous report as received from a nurse refers to a 12 month old patient. On 08-SEP-2014, the patient was vaccinated a 4th dose of ROTATEQ (dose 2ml, lot# and expiration date were unkonwn) oral. This patient had previously completed the ROTATEQ series, with doses given on: 26-NOV-2014, 23-JAN-2014, 14-MAR-2014. No adverse effect was reported. Additional information has been requested.
This MA was in room at 1527 to ask patient how she was feeling and she reported she was feeling fine and wanted to know why she had to take the next day off post second vaccine. RN walked in seconds after this MA and asked patient how she was feeling with RN and patient reported she was feeling "queasy and lightheaded." Vitals were obtained. 1528 patient was moved to exam table to sit down. 1531 vitals obtained and laid down due patient feeling lightheaded and Dr came in from UCC to exam at bedside. Dr advised to rest x10 minutes and come back for exam after 10 minutes. 1544 patient sat up again, vitals obtained, patient reports mouth felt numb, denies SOB. Dr back in room at 1547, exam completed patient states felt short of breath, patient transferred to convenient care at 1551 by w/c.  Heart Rate Peripheral   69 bpm  (DEC 29 15:58) Resp Rate         16 brpm  (DEC 29 15:58) SBP      H 145mm hg  (DEC 29 15:58) DBP      85 mm hg  (DEC 29 15:58) SpO2      100 %  (DEC 29 15:58)   General:  Alert and oriented, Mild distress.   Eye:  Pupils are equal, round and reactive to light, Intact accommodation, Extraocular movements are intact.   HENT:       Throat: Uvula ( Not edematous ), Pharynx ( Not edematous, Not erythematous ).   Respiratory:  Lungs are clear to auscultation, Respirations are non-labored, Breath sounds are equal.   Cardiovascular:  Normal rate, Regular rhythm.   Integumentary:  Warm, Dry, At 1605, a circumferential hive developed on her anterior neck.  It was demarcated and measured 5.0 cm x 6.0 cm.  It continued to enlarge and spread towards her ears.  Later recheck, hives were starting to fade..   Neurologic:  Alert, Oriented, Cranial Nerves II-XII are grossly intact, Normal gait, Normal balance.        Orientation: Oriented X 4.   Psychiatric:  Cooperative, Appropriate mood & affect.    From Note: 1.  Pt was stable after medications (diphenhydramine 25 mg PO x 1, epinephrine 0.3 mg IM x 1) were administered; Hives improved, as well as the "head heaviness" and lightheadedness 2.  Pt's husband arrived at clinic to accompany pt and to transport her home 3.  Discussed warning signs to monitor for.  Pt and husband were advised to call 911 instead of driving to the hospital if any developed, especially due to the bad weather this late afternoon 4.  Pt inquired whether or not to get the second vaccine, since she already has a date scheduled.   Spoke with pt via phone at 1738.  She arrived home safely and states she still feels better.  I advised that she should wait regarding the second vaccination dose and that she should discuss this further with her PCP. 5.  Pt ambulated the hallways with Nursing staff nearby, and tolerated this well without being dizzy or lightheaded 6.  Full PPE worn during this visit -- Gown, gloves, N-95 mask, face shield.
Vaccine that administered beyond use date after the thaw process; This spontaneous case was reported by a paramedic and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030h21b) for COVID-19 prophylaxis.     It was unknown if patient had been diagnosed with or tested positive for COVID-19, or if patient had chronic or long lasting health conditions. It was unknown if patient had any acute illness at the time of vaccination and up to one month before.     On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not provided by the reporter. On 10-Jun-2022, the vaccination facility was made aware of administration of vaccines beyond use date after the thaw process while audit was conducted. Patient got Moderna vaccine and the Ndc code was reported. Patient had reported no adverse reactions after the administration of vaccine. Treatment information was not provided.   This case was linked to MOD-2022-542869 (Patient Link).
Tingling sensation on both hands and feet, body ache and fever the day 24 hrs after the 2nd dose. Aleve  200mg taken which alleviated the body ache and fever. Tingling sensation was still there but less. On and off Headache and feeling of fatigue and sleepiness started 1 day after shot given.
Moderna COVID-19 Vaccine EUA 02/18/21 - achy back and neck (beyond ?normal? for me) - left arm sore 3/10 - pink rash near injection site - temp: 100.3 (normal 98 or below);  Tylenol was not strong enough to relieve discomfort - took Aleve;  improved on Friday 02/19/21;  much better on Saturday 02/20/21;  back to my ?normal? Sunday 02/21/21
Pt experienced soreness and somre erythema for TRUMENBA which began a few hours after it was administered, the symptoms for Menactra began next day. Minimal erythema and edema over both deltoid areas where immunizations were applied. Minimal tenderness to palpation. Pt to take ibuprofen prn for pain and inflammation and to apply cool/warm compresses. Symptoms have improved since symptoms initially appeared, pt has been afebrile.
I started having a sore throat feeling about February 22. By the 23rd it felt like a mild case of the flu with a cough and body aches. I tested positive on February 23 via a home COVID-19 test. I contacted my doctor, and she sent out a prescription for an antivirals. After finishing the 5 days, I retested, and I was negative. I was symptom free at that time outside of a lingering cough.
No adverse effects reported.; an unspecified number of patients received improperly stored dose of RECOMBIVAX, GARDASIL 9, MMRII, or PROQUAD; The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify.  Follow-up information has been received from the practice manager on 18-SEP-2018.  This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided.       On 10-APR-2018, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (strength and route were unknown) (lot# reported as No14633 which was verified as not valid and expiration date reported as 07-NOV-2018) for prophylaxis (Incorrect product storage). The sterile diluent (MERCK STERILE DILUENT) was properly stored. No adverse event was reported.  The excursion temperature on 22-SEP-2017, 17-OCT-2017, 06-DEC-2017, 07-DEC-2017, 30-JAN-2018, 23-FEB-2018, 18-MAY-2018, 05-JUL-2018, 15-AUG-2018 was 6 degree Celsius for maximize 8.75 hours. The excursion temperature on 02-MAR-2018, 27-AUG-2018 was 7 degree Celsius for maximize 8.75 hours. The excursion temperature on 07-DEC-2017 was 8 degree Celsius for maximize 15 hours. The call was not because of data logger.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1809USA003709: US-009507513-1810USA001951: US-009507513-1810USA001952: US-009507513-1810USA001953: US-009507513-1810USA001954: US-009507513-1810USA001955: US-009507513-1810USA001956: US-009507513-1810USA001957: US-009507513-1810USA001959:
Patient broke out in hives on insides of legs first. Spread to front torso, down legs, armpits, and spots on arms over subsequent 24 hrs. Recommended by physician to give Benadryl. Benadryl was given.
02/27/21: Full body aches, fever, chills, nausea x 18 hours 03/12/21:  14 days post vaccination. Body rash that started on neck, chest and back, progressed, despite taking Benadryl and Hydrocortisone cream.  Seen in urgent care at hospital when entire body covered in red rash all over torso, neck, head and extremities.  Itchy.  Prescribed Prednisone and Benadryl.  Rash ongoing as this is being reported.
Chills; dizzy; aching all over; fever; felt like she had the flu; joint pain that was quite painful all over/had an attack with pains in her shoulders/joint pain attack; This is a spontaneous report from a contactable consumer. An 85-year-old female patient received second dose of (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: and expiry date was not provided) via an unspecified route of administration, on 16Feb2021 (at the age of 85-year-old), as a single dose for COVID-19 immunization. Patient's medical history and concomitant medications were not reported. Historical vaccine included first dose of (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: and expiry date was not provided) via an unspecified route of administration, on 25Jan2021 (at the age of 85-year-old), as a single dose for COVID-19 immunization. It was reported that the events happened after the second dose of the vaccine. The patient received the second dose of the Pfizer BioNTech COVID 19 vaccine on 16Feb2021. A couple of days after, on 19Feb2021, patient had chills, patient was dizzy, aching all over, had a fever, and it felt like she had the flu. These symptoms resolved within a day, she felt better the next morning when she woke up. A few weeks later, the patient thinks it was 01Mar2021, she began having joint pain that was quite painful all over. The joint pain seems to be worse at night than during the day. Last night the patient had a joint pain attack, it was extreme, the patient wanted to die. It was in the patient's shoulders, knees, and joints. Patient has been prescribed 3 or 4 medications and opioids, none of which have worked.  She took one of the pills last night and 6 hours later, she had an attack with pains in her shoulders, knees and joints. The reporter and patient called 911 but they did not take the patient to the hospital or admit her. The patient took one of her opioids last night- Tramadol HCL 50mg and 6 hours later the joint pain attack happened. The Tramadol did not help the patient's pain, in fact it made it worse. Tramadol HCL 50mg tablet- NDC, lot, expiration date unknown. The medication is in a pharmacy bottle and the print is so small the patient can hardly read it. The patient was following up with her doctor who also prescribed a steroid which she will pick up later today. The reporter and patient completed the VAERS form already on this event. The patient had blood work done yesterday (18May2021), and her doctor said there was no indication of anything wrong with the blood work. Outcome of the events chills, dizzy, aching all over, fever and felt like she had the flu was recovered on 20Feb2021 and joint pain was recovered on an unknown date in 2021.  Information on Lot/Batch number was available. Additional information has been requested.
This spontaneous report was received from a registered nurse and refers to a 16 year old male patient. The patient's concurrent conditions, medical history and concomitant therapies were not reported. On 30-SEP-2016, the patient was vaccinated with an improperly stored dose of VARIVAX, lot # M008173 with expiration date of 16-FEB-2018 (dose, route and frequency were not reported) for prophylaxis. It was stated that the vaccine underwent a temperature excursion of 6 degrees Fahrenheit to 14 degrees Fahrenheit for 3 days. It was reported that there was no need to repeat vaccine. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1705USA014053.
Patient reports on Monday evening 9-16-2018 around dinnertime that she started to experience nausea/vomiting/diarrhea and low grade fever x 3 days.
black and blue mark at the injection site/The mark is about a 2 inch diameter; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE DISCOLOURATION (black and blue mark at the injection site/The mark is about a 2 inch diameter) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     Concomitant products included BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE (NEOSPORIN [BACITRACIN ZINC;NEOMYCIN SULFATE;POLYMYXIN B SULFATE]) for an unknown indication.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced VACCINATION SITE DISCOLOURATION (black and blue mark at the injection site/The mark is about a 2 inch diameter). At the time of the report, VACCINATION SITE DISCOLOURATION (black and blue mark at the injection site/The mark is about a 2 inch diameter) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient received first dose on 16-Feb-2021 at 12:00 in left arm shoulder deltoid muscle.  Treatment medication was not reported.